Categories: HealthcareNews

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, and Eden Fucci, senior vice president of technical operations, will participate in a virtual fireside chat at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024 at 9:00 a.m. ET.

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

Staff

Recent Posts

Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it…

2 hours ago

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on…

2 hours ago

GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous X-ray and ultrasound solutions

Building on its 125-year legacy of medical imaging innovation and a 16-year relationship with NVIDIA,…

2 hours ago

Apollo Biowellness, Inc., f/k/a Resonate Blends Announces Management Changes

North Bergen, New Jersey--(Newsfile Corp. - March 19, 2025) - Apollo Biowellness, Inc. formerly known…

3 hours ago

Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model

Halifax, Nova Scotia--(Newsfile Corp. - March 19, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

3 hours ago

New Psilocybin Service Center Opens to Support Athletes, Veterans, and Others with Traumatic Brain Injuries

Founded by Former NHL Player and mental health advocate Daniel Carcillo, the Portland center is…

3 hours ago